Imunon IMNN 深 滬
等待開盤 09-17 09:30:00 美东时间
1.41
+0.010
+0.71%
華盛通- 最 高1.48
- 今 開1.40
- 成交量 7.33万股
- 最 低 1.38
- 昨 收 1.40
- 總市值 791.21万
- 52周最高 5.55
- 市盈率 靜 --
- 換手率 1.31%
- 52周最低 1.38
- 委 比 94.53%
- 總股本 561.14万
- 歷史最高 25857.3851
- 量 比 0.26
- 振 幅 7.14%
- 歷史最低 1.38
- 每 手 1
- 風險率 1.13%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Imunon Q2 EPS $(0.54) Beats $(0.93) Estimate
Imunon (NASDAQ:IMNN) reported quarterly losses of $(0.54) per share which beat the analyst consensus estimate of $(0.93) by 41.94 percent. This is a 74.88 percent increase over losses of $(2.15) per share from the same period last year.
08-11 20:02
EXCLUSIVE: Imunon Outlines Accelerated Timeline, Strong Safety Data for Pivotal Ovarian Cancer Study
Clinical-stage biotechnology firm Imunon Inc. (NASDAQ:IMNN) on Thursday announced an update on its pivotal Phase 3 OVATION 3 trial evaluating IMNN-001 in newly diagnosed advanced ovarian cancer patients. The company reported site activation and patient enrollment speeds that significantly outpace or...
07-30 20:30
Exclusive: Imunon Says Lead Drug Continues To Show Promise in Advanced Ovarian Cancer Patients
Imunon Inc. (NASDAQ:IMNN) on Tuesday reported new preliminary findings from its ongoing Phase 2 minimal residual disease (MRD) translational trial. MRD refers to the small number of cancer cells that remain in the body during or after treatment. The data showed that patients receiving IMNN-001 along...
07-21 20:30
IMUNON Receives Independent Data Monitoring Committee Recommended Continuation Of Pivotal Phase 3 OVATION 3 Clinical Trial Of IMNN-001 In Combination With Standard Of Care Neoadjuvant And Adjuvant Chemotherapy In Women With Newly Diagnosed Advanced Ovarian Cancer
IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that the independent Data Monitoring Committee (iDMC) has recommended continuation of the pivotal Phase 3 OVATION 3 clinical trial evaluating IMNN-001 in combination with ...
06-23 20:03
IMUNON Enters Into Definitive Agreements For $10M In Preferred Stock And Secured Notes
Includes up-front issuance of preferred stock for $2.5 million and secured promissory notes for $7.72 millionUniquely structured, flexible financing supports IMUNON's Highly Anticipated Phase 3 OVATION 3 Study of
06-04 20:04
Imunon Reports Q1 2026 Results: Full Earnings Call Transcript
Imunon (NASDAQ:IMNN) released first-quarter financial results and hosted an ear...
05-12 23:54
Imunon Q1 EPS $(0.84) Beats $(1.07) Estimate
Imunon (NASDAQ:IMNN) reported quarterly losses of $(0.84) per share which beat the analyst consensus estimate of $(1.07) by 21.5 percent. This is a 73.33 percent increase over losses of $(3.15) per share from the same
05-12 20:01
Earnings Scheduled For May 12, 2026
Companies Reporting Before The Bell • Sionna Therapeutics (NASDAQ:SION) is proj...
05-12 19:11
美股大行评级 | 美银证券上调闪迪目标价从900美元升至1080美元；纽约梅隆银行、Onto Innovation、安博、美国合众银行等获多家大行上调目标价
今日重点评级关注：Guggenheim：维持AtaiBeckley Inc."买入"评级，目标价从11美元升至16美元；RBC Capital：维持MeiraGTx Holdings"跑赢大市"评级，目标价从16美元升至24美元
04-20 11:33
Maxim Group Initiates Coverage On Imunon with Buy Rating, Announces Price Target of $10
Maxim Group analyst Jason McCarthy initiates coverage on Imunon (NASDAQ:IMNN) with a Buy rating and announces Price Target of $10.
04-17 21:18
